Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma.
复制标题
晚期多发性骨髓瘤患者大剂量化疗后 CD34+ 外周血祖细胞移植。
DOI：
10.1182/blood.v86.1.390.bloodjournal861390
复制
发表时间：
1995
期刊：
影响因子：
20.3
通讯作者：
J. Berenson
中科院分区：
文献类型：
--
作者：
G. Schiller;R. Vescio;C. Freytes;G. Spitzer;F. Sahebi;Myung Lee;Chunjiao Wu;Jing Cao;J. C. Lee;Charlie;Hong;A. Lichtenstein;M. Lill;Jeff M. Hall;R. Berenson;J. Berenson
自体移植治疗晚期恶性肿瘤的一个主要潜在问题是肿瘤细胞的输注。在37例接受清髓性化疗的晚期多发性骨髓瘤患者中进行了一项纯化的CD 34选择性外周血祖细胞（PBPC）移植的多机构研究。在给予中等剂量环磷酰胺、泼尼松和粒细胞集落刺激因子（G-CSF）后14天，中位数为3（范围，2 - 5）次10-L白细胞去除术产生了9.8 x 10（8）/kg（范围，3.7 - 28.3）单核细胞。吸附（色谱柱结合）部分含有5.9 x 10（6）个细胞/kg（范围：1.6 - 25.5）和4.65 x 10（6）个CD 34细胞/kg（范围：1.2 - 23.3）。使用患者特异性互补决定区1（CDR 1）和CDR 3 Ig基因引物的阳性聚合酶链反应的泊松分布分析，在8至14例AML患者的白细胞分离产物中检测到肿瘤，范围为1.13 x 10（4）至2.14 x 10（6）恶性细胞/kg。经CD 34选择后，仅在3名患者的产品中检测到残留肿瘤。总体而言，实现了污染性多发性骨髓瘤细胞的大于2.7- 4.5-log减少。在白消安（14 mg/kg）和环磷酰胺（120 mg/kg）后1天输注CD 34 PBPC，并使用粒细胞-巨噬细胞集落刺激因子直至血液学恢复。中性粒细胞和血小板恢复的中位时间为12天（范围分别为11 - 16天和9 - 52天）。红细胞和血小板输注的中位数分别为7（范围，2 - 37）和3（范围，0 - 85）。接受少于2 x 10（6）CD 34细胞/kg的患者出现显著延长的中性粒细胞减少症、血小板减少症，以及红细胞和血小板输注需求增加。因此，PBPC的CD 34选择显著减少多发性骨髓瘤中的肿瘤污染，并为接受清髓性治疗的患者提供有效的造血支持。
A major potential problem of autologous transplantation in the treatment of advanced malignancy is the infusion of tumor cells. A multi-institutional study of purified CD34-selected peripheral blood progenitor cell (PBPC) transplantation was conducted in 37 patients with advanced multiple myeloma receiving myeloablative chemotherapy. Fourteen days after intermediate-dose cyclophosphamide, prednisone, and granulocyte colony-stimulating factor (G-CSF), a median of 3 (range, 2 to 5) 10-L leukaphereses yielded 9.8 x 10(8)/kg (range, 3.7 to 28.3) mononuclear cells. The adsorbed (column-bound) fraction contained 5.9 x 10(6) cells/kg (range, 1.6 to 25.5) with 4.65 x 10(6) CD34 cells/kg (range, 1.2 to 23.3). Using Poisson distribution analysis of positive polymerase chain reactions with patient-specific complementarity-determining region 1 (CDR1) and CDR3 Ig-gene primers, tumor was detected in leukapheresis products from 8 to 14 unselected patients and ranged from 1.13 x 10(4) to 2.14 x 10(6) malignant cells/kg. After CD34 selection, residual tumor was detected in only three patients' products. Overall, a greater than 2.7- to 4.5-log reduction in contaminating multiple myeloma cells was achieved. CD34 PBPCs were infused 1 day after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg), and granulocyte-macrophage colony-stimulating factor was used until hematologic recovery. The median time to both neutrophil and platelet recovery was 12 days (range, 11 to 16 days and 9 to 52 days, respectively). The median number of erythrocyte and platelet transfusions was 7 (range, 2 to 37) and 3 (range, 0 to 85), respectively. Patients receiving fewer than 2 x 10(6) CD34 cells/kg had significantly prolonged neutropenia, thrombocytopenia, and an increased red blood cell and platelet transfusion requirement. Thus, CD34 selection of PBPCs markedly reduces tumor contamination in multiple myeloma and provides effective hematopoietic support for patients receiving myeloablative therapy.
登录
查看更多内容
高剂量马法兰和粒细胞巨噬细胞集落刺激因子治疗难治性多发性骨髓瘤。
影响因子：
20.3
作者：
Barlogie,B;Jagannath,S;Dixon,DO;Cheson,B;Smallwood,L;Hendrickson,A;Purvis,JD;Bonnem,E;Alexanian,R
通讯作者：
Alexanian,R
自体骨髓移植联合药物清除的I期研究。
DOI：
10.1200/jco.1991.9.12.2210
发表时间：
1991
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Rowley,SD;Miller,CB;Piantadosi,S;Davis,JM;Santos,GW;Jones,RJ
通讯作者：
Jones,RJ
影响因子：
3.6
作者：
CAMPBELL, MJ;ZELENETZ, AD;LEVY, R
通讯作者：
LEVY, R
乳腺癌或神经母细胞瘤患者输注 CD34+ 骨髓细胞后的植入。
影响因子：
20.3
作者：
Berenson,RJ;Bensinger,WI;Hill,RS;Andrews,RG;Garcia-Lopez,J;Kalamasz,DF;Still,BJ;Spitzer,G;Buckner,CD;Bernstein,ID
通讯作者：
Bernstein,ID
白消安和环磷酰胺为多发性骨髓瘤患者进行同种异体骨髓移植做准备的 I 期研究。
DOI：
10.1200/jco.1992.10.9.1492
发表时间：
1992
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Bensinger,WI;Buckner,CD;Clift,RA;Petersen,FB;Bianco,JA;Singer,JW;Appelbaum,FR;Dalton,W;Beatty,P;Fefer,A
通讯作者：
Fefer,A